Up and down waves of glycemic control and lower-extremity amputation in diabetes
Open Access
- 6 July 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 20 (1), 1-4
- https://doi.org/10.1186/s12933-021-01325-3
Abstract
Lower extremity amputations (LEA) are associated with a high mortality and medical expenditure. Diabetes accounts for 45% to 70% of LEA and is one of the most potent risk factors for peripheral artery diseases (PAD). The existence of a link between the recent relaxation of glycemic targets and the resurgence of LEA is suggested from the analysis of adult participants in the National Health and Nutrition Examination Survey (NHANES) between 2010 and 2015, when diabetes-related LEA increased by more than 25% associated with a decline in glycemic control. Indeed, in “the perfect wave” of NHANES, including the years 2007–2010, there was the highest number of diabetic people with hemoglobin A1c (HbA1c), non-high-density lipoprotein (HDL) cholesterol and blood pressure levels at their respective targets, associated with the lowest number of LEA. Until now, the ACCORD study, testing the role of aggressive vs conventional glucose control, and the LEADER trial, evaluating the effects of liraglutide versus placebo, have shown a reduced incidence of LEA in people with type 2 diabetes. The results of ongoing clinical trials involving glucagon-like peptide-1 receptor agonists (GLP-1RA, liraglutide or semaglutide) hopefully will tell us whether the wider use of these drugs may provide additional vascular benefits for diabetic people affected by PAD to decrease their risk of LEA.Keywords
Funding Information
- Associazione Salute con Stile
This publication has 20 references indexed in Scilit:
- Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 DiabetesJAMA Internal Medicine, 2018
- The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER TrialDiabetes Care, 2018
- Diabetic Foot Ulcers and Their RecurrenceThe New England Journal of Medicine, 2017
- Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular OutcomesDiabetes Care, 2016
- Changes in Diabetes-Related Complications in the United States, 1990–2010The New England Journal of Medicine, 2014
- Intensive glucose control and macrovascular outcomes in type 2 diabetesDiabetologia, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes MellitusAnnals of Internal Medicine, 2004